INNUPREC (Nutrigenetic Intervention for the Prevention of Cardiovascular Disease)
Launched by UNIVERSITY OF GUADALAJARA · Feb 20, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The INNUPREC trial is studying how specific dietary changes can help improve heart health in people with abdominal obesity, a condition where excess fat is stored around the stomach. This trial is particularly important because abdominal obesity affects many people in Mexico and is linked to a higher risk of heart disease. Researchers want to see if a personalized nutrition plan, based on genetic factors, can positively impact heart-related health markers and overall well-being.
To participate in this study, individuals must be between 30 and 65 years old, have a waist measurement that indicates abdominal obesity (88 cm or more for women and 102 cm or more for men), and agree to take part in the trial by signing an informed consent form. Participants will be divided into two groups, one receiving the personalized dietary intervention and the other serving as a control. The study will last for two months, during which participants will have their dietary habits and health markers monitored at the start, halfway through, and at the end. This trial is not yet recruiting, so there will be more information available soon for those interested in joining.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 30-65 years of age
- • Subjects who agree to participate in the study and all signed informed consent
- • Women with a waist circumference ≥ 88 cm and men ≥ 102 cm according to NCEP/ATPIII.
- Exclusion Criteria:
- • Currently consuming any of the following drugs: NSAIDs, anticoagulants, hypoglycemic, or hypolipemic drugs
- • Diagnosed autoimmune diseases
- • Diagnosed cancer
- • Pregnancy and breastfeeding
- • Subjects who have undergone a dietary intervention at the time or up to 3 months prior
- • Subjects who wish to abandon the study
About University Of Guadalajara
The University of Guadalajara, a prominent academic institution in Mexico, is dedicated to advancing medical research and improving healthcare outcomes through innovative clinical trials. With a commitment to scientific excellence and ethical standards, the university collaborates with various stakeholders to conduct rigorous studies aimed at addressing critical health challenges. Its multidisciplinary approach harnesses the expertise of faculty and researchers across diverse fields, fostering a robust environment for the development of groundbreaking treatments and interventions. By actively contributing to the global body of medical knowledge, the University of Guadalajara plays a vital role in enhancing patient care and promoting public health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guadalajara, Jalisco, Mexico
Patients applied
Trial Officials
Wendy Campos-Perez, PhD
Study Chair
University of Guadalajara
Alondra Mora-Jiménez, Graduate
Study Chair
University of Guadalajara
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported